ライフサイエンスコーパス: hemodialysis

1 common among patients receiving maintenance hemodialysis.

2 mL/min/1.73 m2 and 699 (3.4%) were receiving hemodialysis.

3 and atrophy in brain imaging of patients on hemodialysis.

4 children whose initial treatment modality is hemodialysis.

5 en in ESRD patients receiving emergency-only hemodialysis.

6 d vascular calcification (VC) in patients on hemodialysis.

7 apy did not decrease platelets compared with hemodialysis.

8 emodialysis due to the circulatory stress of hemodialysis.

9 avoid the cognitive complications seen with hemodialysis.

10 in patients receiving scheduled maintenance hemodialysis.

11 with hyperphosphatemia receiving maintenance hemodialysis.

12 urs after beginning of continuous venovenous hemodialysis.

13 comorbidities, and duration and frequency of hemodialysis.

14 ompared with those treated with intermittent hemodialysis.

15 ents with end-stage kidney disease receiving hemodialysis.

16 ents with ESRD but declines after initiating hemodialysis.

17 ong these, 30 decreased significantly during hemodialysis.

18 rmacokinetics at steady state in patients on hemodialysis.

19 oo hemodynamically unstable for intermittent hemodialysis.

20 in patients with hyperphosphatemia receiving hemodialysis.

21 in patients with hyperphosphatemia receiving hemodialysis.

22 The second patient received hemodialysis.

23 ravenously every 2 weeks for 12 weeks during hemodialysis.

24 ptimal in the majority of patients receiving hemodialysis.

25 nducted with 176 adults with ESRD on regular hemodialysis.

26 Two children required hemodialysis.

27 e (PTH) concentrations in patients receiving hemodialysis.

28 pressor circulatory support and intermittent hemodialysis.

29 ated to potassium homeostasis in patients on hemodialysis.

30 rtality in patients with ESRD on maintenance hemodialysis.

31 end-stage renal disease patients who undergo hemodialysis.

32 t of arteriovenous synthetic grafts used for hemodialysis.

33 nd 34 examinations in 27 patients undergoing hemodialysis.

34 were on peritoneal dialysis, and 57 were on hemodialysis.

35 s from patients with CKD or those undergoing hemodialysis.

36 hrough peritoneal dialysis, aquaphoresis, or hemodialysis.

37 mortality among patients receiving in-center hemodialysis.

38 llograft rejection requiring reinitiation of hemodialysis.

39 tracellular phosphate in patients undergoing hemodialysis.

40 may not be optimal among patients requiring hemodialysis.

41 onary artery disease, mechanical support, or hemodialysis.

42 2 antibodies in patients receiving in-center hemodialysis.

43 nitive impairment in patients on maintenance hemodialysis.

44 er 1.73 m(2)), and 20 with ESKD treated with hemodialysis.

45 cline after 7 hours of continuous venovenous hemodialysis (16 mV; 13-21 and 7 mV; 6-13 and 9 mV; 8-13

46 ith AMI, 1398 (0.5%) were on dialysis (73.6% hemodialysis; 26.4% peritoneal dialysis).

47 an acute decrease in renal perfusion during hemodialysis, a first step toward pathophysiologic chara

48 Among patients undergoing hemodialysis, a high-dose intravenous iron regimen admin

49 UTs) are difficult to remove by conventional hemodialysis; a high degree of protein binding reduces t

50 Conclusion Patency-adjusted payments for hemodialysis access maintenance differed by physician sp

51 cost-effective, intervention for increasing hemodialysis adherence in high-risk patients, especially

52 eadmissions are common in patients receiving hemodialysis and costly to Medicare.

53 between objective and subjective effects of hemodialysis and decreases of intracellular Pi and betaA

54 n chronic renal failure patients who require hemodialysis and details the dosimetry results obtained

55 detected in 19 patients (25%): one required hemodialysis and four underwent renal transplant.

56 te, serum creatinine level, and the risk for hemodialysis and metachronous disease were calculated.

57 ment of HCV-positive patients on maintenance hemodialysis and performed a random effects meta-analysi

58 Hemodialysis and peritoneal dialysis were the only forms

59 resence of HDL from CKD rabbits, patients on hemodialysis and peritoneal dialysis, and HNE-modified H

60 ed to supratherapeutic levels in patients on hemodialysis and should be avoided.

61 d an AVF created within 6 months of starting hemodialysis and used for dialysis (matured) within 6 mo

62 d patient improved immediately upon starting hemodialysis and was extubated within 48 hours and disch

63 tly different from the decline with standard hemodialysis), and ten of the 15 patients showed improve

64 s 2.5%, respectively, among 4297 patients on hemodialysis, and 1.4% versus 1.6%, respectively, among

65 ersus 19.9%, respectively, among patients on hemodialysis, and 14.0% versus 23.0%, respectively, amon

66 s from 15 healthy volunteers, 25 patients on hemodialysis, and 20 on peritoneal dialysis.

67 Ts), including ultrafiltration, intermittent hemodialysis, and continuous RRT are used to manage comp

68 d multiorgan failure requiring vasopressors, hemodialysis, and mechanical ventilation.

69 plantation, infection, thromboembolic event, hemodialysis, and readmission).

70 tatus (KPS 10%-40%), living donor LT, pre-LT hemodialysis, and the donor risk index (all P < .001).

71 lysis independence rates at 6 and 12 months, hemodialysis- and chemotherapy-related adverse events, a

72 , hepatocellular carcinoma, paracentesis, or hemodialysis; and discharge against medical advice were

73 Patients needing hemodialysis are advised to have arteriovenous fistulas

74 Patients with CKD who are on hemodialysis are hyporesponsive to erythropoiesis-stimul

75 cal trials to inform practice in maintenance hemodialysis are limited.

76 t in Chinese older adult patients undergoing hemodialysis are not clear, we aimed to identify the ext

77 Creation of a hemodialysis arteriovenous fistula (AVF) causes aberrant

78 eatment of stenotic lesions in dysfunctional hemodialysis arteriovenous fistulas during the 6 months

79 yperplasia development in a porcine model of hemodialysis arteriovenous graft stenosis.

80 ins from the blood increases the efficacy of hemodialysis, as well as the survival rate, in CKD patie

81 is serum sodium >=135 mM, and were receiving hemodialysis at home or a self-care satellite facility.

82 mal hyperplasia (VNH) at the outflow vein of hemodialysis AVF is a major factor contributing to failu

83 y of patients aged >/=18 years who initiated hemodialysis between 2004 and 2012 at five Canadian dial

84 Thirty bicarbonate hemodialysis (BHD) patients were randomized 1:1 to conti

85 to arteriovenous fistula (AVF) creation for hemodialysis but cannot demonstrate the central vasculat

86 a standard treatment for patients undergoing hemodialysis, but comparative data regarding clinically

87 n K2 improve vitamin K status in patients on hemodialysis, but have no significant favorable effect o

88 ased risk of mortality in patients receiving hemodialysis, but high values are a marker for poor nutr

89 (AVF) are the most common access created for hemodialysis, but up to 60% do not sustain dialysis with

90 lar Phosphate Concentration Evolution During Hemodialysis by MR Spectroscopy (CIPHEMO), NCT03119818.

91 Arteriovenous (AV) fistulas for hemodialysis can lead to cardiac volume loading and incr

92 for the prevention of CLABSI in 3 settings: hemodialysis, cancer treatment, and home parenteral nutr

93 distinct and clinically important settings (hemodialysis, cancer treatment, and home parenteral nutr

94 ted through Washington University-affiliated hemodialysis centers involving ESRD patients with poor a

95 Fluid overload in patients undergoing hemodialysis contributes to cardiovascular morbidity and

96 roblematic, and no formal recommendations on hemodialysis currently exist.

97 common among patients receiving maintenance hemodialysis, data on their acceptance of treatment and

98 tes, hypertension, congestive heart failure, hemodialysis-dependence, cancer diagnosis, chronic obstr

99 hypoperfusion that can occur during routine hemodialysis due to the circulatory stress of hemodialys

100 trate anticoagulation-continuous veno-venous hemodialysis during a 3-year period (n = 1,070) were inc

101 nsplantation; and 1 patient required further hemodialysis during follow-up.

102 g/dl or >=50%, respectively, or the need for hemodialysis during index hospitalization.

103 All patients received continuous veno-venous hemodialysis during the LT.

104 Cirrhosis and duration of hemodialysis during the study period were associated wit

105 Intensive hemodialysis (eight 5-hour sessions over 10 days) with e

106 The options for KRT include hemodialysis (either in-center or at home), peritoneal d

107 loramines in the water prior to entering the hemodialysis equipment is essential.

108 The capacity of the hemodialysis equipment to clear chloramine can vary as a

109 Patients with end-stage renal disease on hemodialysis (ESRD-HD) and aortic stenosis have poor pro

110 Patients with CKD on hemodialysis exhibit increased cardiovascular risk.

111 HDL from CKD rabbits and patients on hemodialysis exhibited an impaired ability to inhibit pl

112 eases the likelihood that patients receiving hemodialysis experience a 30-day readmission unrelated t

113 Patients undergoing hemodialysis experience transient decline in cerebral bl

114 rent recommended treatment for dysfunctional hemodialysis fistulas, yet long-term outcomes of this tr

115 = 14), infusion of SNF472 (~ 7 mg/kg) during hemodialysis for 12 weeks inhibited calcium phosphate cr

116 ith CVC (N = 274), infusion of SNF472 during hemodialysis for 52 weeks inhibited calcium phosphate cr

117 domized 2141 patients undergoing maintenance hemodialysis for ESKD to a high-dose or a low-dose IV ir

118 amples from 356 patients receiving in-center hemodialysis for SARS-CoV-2 antibodies.

119 Exclusion criteria included hemodialysis frequency >3.5 times per week and use of so

120 to identify all patients receiving in-center hemodialysis from 2006 through 2015 and to track dialysi

121 stem to identify ESKD patients who initiated hemodialysis from 2006 to 2013 and then identified those

122 events recorded among patients dependent on hemodialysis from January 2009 through September 2015.

123 luded 7301 patients >=67 years who initiated hemodialysis from July 2010 to June 2012 with a catheter

124 group vs 33.3% (n = 16) in the conventional hemodialysis group (between-group difference, 8.0% [95%

125 months was 41.3% (n = 19) in the high-cutoff hemodialysis group vs 33.3% (n = 16) in the conventional

126 ed adverse events was 43% in the high-cutoff hemodialysis group vs 39% in the conventional hemodialys

127 emodialysis group vs 39% in the conventional hemodialysis group; chemotherapy-related serious adverse

128 were incubated with HDL from CKD rabbit and hemodialysis groups than with HDL from the control group

129 ved a cohort of 115,425 patients on incident hemodialysis >/=67 years old from the US Renal Data Syst

130 HDL from CKD rabbits and patients on hemodialysis had HNE adducts.

131 nterview with patients receiving maintenance hemodialysis had no effect on their acceptance of treatm

132 ip between BP and downstream ischemia during hemodialysis has not been characterized.

133 Because patients on hemodialysis have a high background hospitalization rate

134 Interventional studies in hemodialysis have been limited and inconsistent in their

135 on in patients with ESKD receiving in-center hemodialysis have been rapidly implemented across the gl

136 ronger among children initially treated with hemodialysis (hazard ratio, 1.56, 95% confidence interva

137 mic toxins (PBUTs) are poorly removed during hemodialysis (HD) due to their low free (dialyzable) pla

138 Hemodialysis (HD) has limited efficacy towards treatment

139 bolic syndrome (MetS) (n = 13), and diabetic hemodialysis (HD) patients (n = 24).

140 ise (ID) programs are effective and safe for hemodialysis (HD) patients to avoid functional deteriora

141 Patients undergoing hemodialysis (HD) through a prevalent central venous cat

142 nal study comparing outcomes on conventional hemodialysis (HD) versus postdilution online HDF in chil

143 ) maturation prevent optimal fistula use for hemodialysis; however, the mechanism of venous remodelin

144 n among women on peritoneal dialysis than on hemodialysis (HR, 0.47; 95% CI, 0.41 to 0.55).

145 nts (40%), and renal insufficiency requiring hemodialysis in 2 of 5 patients (40%).

146 included 258,510 patients receiving chronic hemodialysis in 2005-2013.

147 ents with end-stage kidney disease receiving hemodialysis in addition to standard care.

148 mong 111,653 patients undergoing maintenance hemodialysis in facilities operated by a large dialysis

149 Among patients dependent on hemodialysis in the United States, both short-term and l

150 In adults with Medicare receiving hemodialysis in the United States, we used multinomial l

151 a cohort of Medicare beneficiaries receiving hemodialysis included in the US Renal Data System regist

152 Primary end point was hemodialysis independence at 3 months; secondary end poi

153 To compare the hemodialysis independence rate among patients newly diag

154 The hemodialysis independence rate at 3 months was 41.3% (n

155 ependence at 3 months; secondary end points: hemodialysis independence rates at 6 and 12 months, hemo

156 Whether hemodialysis-induced circulatory stress affects renal pe

157 esearch shows that dialysate cooling reduces hemodialysis-induced circulatory stress and protects the

158 e a reference to another organ vulnerable to hemodialysis-induced ischemic injury, we also used echoc

159 The optimal BP target for patients receiving hemodialysis is unknown.

160 cy of cognitive impairment in individuals on hemodialysis is well characterized.

161 ents with end-stage renal disease undergoing hemodialysis, it was recently shown that the heart rate

162 with other dialysis populations, identifying hemodialysis itself as a possible factor.

163 (n=91), or placebo (n=91) by infusion in the hemodialysis lines thrice weekly during hemodialysis ses

164 t low and medium volume centers, infections, hemodialysis, liver biopsy, and length of stay > 10 days

165 Patients on hemodialysis may be at increased risk for cerebral ische

166 Individuals receiving maintenance hemodialysis may be particularly susceptible to the leth

167 enol, epidural anesthesia, and postoperative hemodialysis may have contributed to systemic hypotensio

168 tenol, epidural anesthesia and postoperative hemodialysis may have contributed to systemic hypotensio

169 During the first hour of hemodialysis, mean phosphatemia decreased significantly

170 toward pathophysiologic characterization of hemodialysis-mediated RRF decline.

171 In maintenance hemodialysis (MHD) patients, low protein intake is assoc

172 s, such as individuals receiving maintenance hemodialysis, might increase the risk of infections.

173 Adjusted state-specific hemodialysis mortality rates were determined in 3-year i

174 rance of creatinine < 10 mL/min) patients on hemodialysis (n = 40).

175 the leading cause of death among patients on hemodialysis, occurs frequently within outpatient dialys

176 , 80% of patients in the United States start hemodialysis on a central venous catheter (CVC).

177 th incident ESKD aged >=66 years who started hemodialysis on a CVC in July 2010 through 2013.

178 The immediate and longer-term effects of hemodialysis on cerebral circulation, cerebral structure

179 scheduled hemodialysis receive intermittent hemodialysis only when life-threatening conditions arise

180 and renal failure only represent 2% to 5% in hemodialysis or transplantation.

181 Requiring posttransplant hemodialysis (OR = 3.69; 95% CI = 2.13-6.37) or surgical

182 (1) versus 6.1% (7) required postprocedural hemodialysis (P<0.05).

183 xplained risk of sudden cardiac death in the hemodialysis patient population.

184 We conducted a cross-sectional study of 613 hemodialysis patients aged 50 to 80 from 11 centers in B

185 oxide (TMAO) with cardiovascular outcomes in hemodialysis patients and assessed whether this associat

186 mples and in vivo heart rate measurements in hemodialysis patients and healthy individuals.

187 Falls occur in 28% of hemodialysis patients and increase the risk of physical

188 ociation between HSV-1 and HCMV was found in hemodialysis patients and severe periodontitis was also

189 mens in the treatment of HCV infection among hemodialysis patients are both effective and safe.

190 In-center hemodialysis patients are disproportionately affected by

191 metal concentrations of incident or chronic hemodialysis patients associated with the observed ESA r

192 ion associates with cardiovascular events in hemodialysis patients but the effects differ by race.

193 To better understand in incident hemodialysis patients how sex and race/ethnicity are ass

194 retrospective cohort study of emergency-only hemodialysis patients in the Harris Health System in Hou

195 L5% was higher in hemodialysis patients in whom ischemic lower-extremity P

196 red (3.03% [IQR, 2.36-4.54], n = 22) than in hemodialysis patients in whom PAD did not occur (1.13% [

197 he 1-year risk of sudden cardiac death among hemodialysis patients initiating SSRIs with a higher pot

198 associated with arteriovenous fistula use in hemodialysis patients is due to the avoidance of cathete

199 is C virus (HCV) infection among maintenance hemodialysis patients is implicated in increased morbidi

200 in (WT-hbeta(2)m) in the joints of long-term hemodialysis patients is the hallmark of dialysis-relate

201 o amyloid plaques in the joints of long-term hemodialysis patients is the hallmark of dialysis-relate

202 tly renal clearance, treatment management in hemodialysis patients may be problematic, and no formal

203 ed with EV from healthy subjects, those from hemodialysis patients reduced angiogenesis and increased

204 All hemodialysis patients showed higher plasma levels of end

205 The study included 30,932 (47.1%) hemodialysis patients who initiated SSRIs with higher QT

206 Transplant Recipients, we identified 15 125 hemodialysis patients who underwent first deceased trans

207 ethnic disparities in all-cause stroke among hemodialysis patients with atrial fibrillation are parti

208 on is a major goal in the management of ESKD hemodialysis patients with atrial fibrillation, investig

209 The study included 56,587 ESKD hemodialysis patients with atrial fibrillation.

210 From 1/2012 to 8/2015, 232 chronic hemodialysis patients with central venous catheters as v

211 Conclusion: In hemodialysis patients with thyroid cancer, an (131)I act

212 Alterations in hemodialysis patients' serum trace metals have been docu

213 to increase coronary artery disease risk in hemodialysis patients, but its effect on the risk of per

214 cognitive impairment in Chinese older adult hemodialysis patients, with varying severity and concomi

215 linked to thrombotic events and mortality in hemodialysis patients.

216 ions, ScvO2 has received little attention in hemodialysis patients.

217 ic lower-extremity PAD developed in 24.4% of hemodialysis patients.

218 (LCV) for one year's worth of data from 580 hemodialysis patients.

219 ), and 94 (75%) countries had facilities for hemodialysis, peritoneal dialysis, and kidney transplant

220 (34%) countries in Africa had facilities for hemodialysis, peritoneal dialysis, and kidney transplant

221 Hemodialysis, peritoneal dialysis, and transplantation s

222 evalence of asymptomatic disease in an adult hemodialysis population has not been reported.

223 the relative cardiac safety of SSRIs in the hemodialysis population is unknown.

224 We found no excess mortality in the hemodialysis population when compared with mean mortalit

225 high rate of cardiovascular mortality in the hemodialysis population, clinicians are obligated to exp

226 seroprevalence of SARS-CoV-2 antibodies in a hemodialysis population, we used the Abbott IgG assay wi

227 ifferentially affect cardiac outcomes in the hemodialysis population.

228 es to maximize stroke prevention in minority hemodialysis populations should be further investigated.

229 One of the fundamental goals of the hemodialysis prescription is to maintain serum potassium

230 ot provide undocumented immigrants scheduled hemodialysis receive intermittent hemodialysis only when

231 tigate whether lower dialysate sodium during hemodialysis reduces left ventricular mass, we conducted

232 The incidence of hemodialysis-related adverse events was 43% in the high-

233 e origin of phosphate that is removed during hemodialysis remains unclear; only a minority comes from

234 o hip fracture risk in patients with ESKD on hemodialysis remains unknown.

235 During standard hemodialysis, renal perfusion decreased 18.4% (P<0.005)

236 ator liberation, and acute kidney injury +/- hemodialysis requirement.

237 Apixaban 2.5 mg twice daily in patients on hemodialysis resulted in drug exposure comparable with t

238 de (n = 503) or placebo (n = 513) after each hemodialysis session for 26 weeks.

239 a were acquired every 152 seconds during the hemodialysis session.

240 In all, 23.5% of hemodialysis sessions featured cerebral ischemia; 31.9%

241 was insufficient to determine whether longer hemodialysis sessions improve outcomes.

242 s prospectively gathered from 635 real-world hemodialysis sessions in 58 prevalent patients.

243 It allows prolonged hemodialysis sessions in critically ill patients without

244 Two hemodialysis sessions in the metabolic radiotherapy unit

245 so recommend dosimetry monitoring during the hemodialysis sessions performed after therapeutic dose a

246 the hemodialysis lines thrice weekly during hemodialysis sessions.

247 y before, 3 hours into, and 15 minutes after hemodialysis sessions.

248 ons resulted in savings of $68721.03 for the hemodialysis setting, $85061.41 for the cancer setting,

249 ffective, compared with heparin locks in the hemodialysis setting, an 88.00% chance in the cancer tre

250 s bacteremia (RB) matched by sex, age, race, hemodialysis status, diabetes mellitus, and presence of

251 otal of 1232 white and black patients of the Hemodialysis Study, and analyzed the association of TMAO

252 is less well defined for patients receiving hemodialysis than for those receiving peritoneal dialysi

253 dy drug was administered 3 times weekly with hemodialysis; the oral study drug was administered daily

254 domly assigned adults undergoing maintenance hemodialysis to receive either high-dose iron sucrose, a

255 with hyperphosphatemia receiving maintenance hemodialysis to receive twice-daily oral tenapanor (3, 1

256 treatment intensity (mechanical ventilation, hemodialysis, tracheostomy, gastrostomy, artificial nutr

257 sy-proven myeloma cast nephropathy requiring hemodialysis treated at 48 French centers between July 2

258 opy examination of patients with ESKD during hemodialysis treatment confirmed that depurated Pi origi

259 he patient underwent an uneventful scheduled hemodialysis treatment via the newly exchanged catheter.

260 nce spectroscopy examination during a 4-hour hemodialysis treatment.

261 reliably the clinical need for antidote and hemodialysis treatment.

262 d with myeloma cast nephropathy treated with hemodialysis using a high-cutoff dialyzer (with very lar

263 me symptoms, and cerebral oxygenation during hemodialysis, using continuous BP and cerebral oxygenati

264 care requires an individualized approach to hemodialysis vascular access, on the basis of each patie

265 and survival differed by treatment modality-hemodialysis versus peritoneal dialysis (P<0.001 for int

266 Patients receiving emergency-only hemodialysis via tunneled catheters have a high CRBSI ra

267 wer tertiles of ScvO2 were older, had longer hemodialysis vintage, lower systolic blood pressure, low

268 The 10-year risk of hemodialysis was 2.3%.

269 l modifications, fibrinogen from patients on hemodialysis was glycosylated and guanidinylated.

270 trials into routine delivery of maintenance hemodialysis, we performed a cluster-randomized, pragmat

271 2015 to 2018, in a cohort of 150 patients on hemodialysis, we performed a set of comprehensive neuroc

272 ults (median age 59 years) receiving chronic hemodialysis, we used transcranial Doppler ultrasound to

273 corporeal membrane oxygenation, and need for hemodialysis were independently associated with chest tu

274 Fifty-five men undergoing maintenance hemodialysis were randomized into either a control (CTL,

275 Thirty-four volatiles decreased during hemodialysis, whereas 26 remained unaffected.

276 experienced delayed graft function requiring hemodialysis which was discontinued on postoperative day

277 al, we randomly assigned patients undergoing hemodialysis who had moderate-to-severe pruritus to rece

278 47 patients with type 2 diabetes mellitus on hemodialysis who participated in the German Diabetes Dia

279 ive HCV genotype 1a male post-LT patients on hemodialysis who were treated with EBR/GZR with or witho

280 Individuals on hemodialysis, who have an unexplained increase in athero

281 anagement of a liver transplant recipient on hemodialysis, who presented with COVID-19 pneumonia, and

282 However, the group initiating hemodialysis with a catheter after failed fistula placem

283 nts in the United States frequently initiate hemodialysis with a central venous catheter (CVC) and su

284 We identified 479 patients starting hemodialysis with a CVC at a large medical center (durin

285 In conclusion, among patients initiating hemodialysis with a CVC, the annual cost of access-relat

286 lan-Meier analysis revealed that patients on hemodialysis with a denser clot structure had increased

287 ed mortality outcomes in patients initiating hemodialysis with a fistula placed first, a catheter aft

288 dentified 300 catheter-dependent patients on hemodialysis with a new AVF created between 2010 and 201

289 status on VC progression in 132 patients on hemodialysis with atrial fibrillation treated with VKAs

290 Our study included 20 patients receiving hemodialysis with calciphylaxis (cases) and 20 patients

291 , and increased serum albumin in patients on hemodialysis with inflammation and hyporesponsiveness to

292 Among patients receiving hemodialysis with moderate to severe secondary hyperpara

293 ls were conducted in 1023 patients receiving hemodialysis with moderate to severe secondary hyperpara

294 e accumulation during continuous veno-venous hemodialysis with regional citrate anticoagulation by in

295 el anti-IL-6 ligand antibody, in patients on hemodialysis with rs855791, a single nucleotide polymorp

296 lcet vs IV placebo in 683 patients receiving hemodialysis with serum parathyroid hormone (PTH) concen

297 with a fistula placed first, 9794 initiated hemodialysis with that fistula, and 8230 initiated dialy

298 ograft futility (death or continued need for hemodialysis within 3 mo posttransplant) for dCLKT (6.3%

299 ograft futility (death or continued need for hemodialysis within 3 months posttransplant) for dCLKT (

300 ciphylaxis (cases) and 20 patients receiving hemodialysis without calciphylaxis (controls) matched fo